There is a subtle but significant shift underway in the world of aesthetic medicine. The patient sitting across the treatment table no longer comes in asking simply to look younger — they arrive wanting healthier skin. They want texture that catches light cleanly, elasticity that rebounds like young tissue, and a clarity that no amount of skincare product has quite been able to deliver. It is a different ambition, and it demands a different class of treatment.

Enter the skin booster: an injectable category that, far from being a single product, has become a philosophy. The premise is regenerative rather than corrective — instead of adding volume or freezing movement, these treatments work with the skin’s own biology to restore what time and environment have taken away. Hydration, collagen synthesis, cellular turnover, wound-healing cascades: the best modern skin boosters speak the language of the skin itself.

Why Skin Boosters Are Becoming a Pillar of Regenerative Treatment

The rise of skin boosters reflects a broader cultural and scientific moment. Patients are better informed than ever, and the language of “regeneration” rather than “correction” has resonated deeply — not only aesthetically but emotionally. There is a meaningful difference between filling a line and encouraging the skin to become the kind of tissue that doesn’t form lines as readily in the first place.

From a clinical standpoint, skin boosters occupy a unique position. They address the dermal layer — the scaffolding beneath the surface — without the risk profile of deeper volumisers or the social downtime of ablative procedures. When well-chosen and well-administered, they produce results that read as health rather than intervention: improved skin tone, reduced pore size, better light-diffusing surface quality, and a measurable increase in dermal density on ultrasound assessment.

The category has also matured. Early iterations were largely synonymous with hyaluronic acid (HA) hydration — micro-injected moisture that plumped fine lines transiently. Today, the field encompasses polynucleotide complexes, growth factor formulations, and hybrid biorevitalisation platforms, each with a distinct mechanism of action and a distinct clinical profile. Understanding these differences is not a luxury for the specialist; it is the foundation of informed patient care.

Three Technologies, Three Philosophies of Skin Boosters

The most clinically relevant skin booster categories currently available are: PDRN-based treatments (typified by Rejuran), Platelet-Derived Growth Factor (PDGF) formulations, and HA-based biorevitalisers such as Juvederm’s Skinvive. Each has advocates and a literature base; none is universally superior for all patients and all concerns. The intelligent clinician treats them as a toolkit, not a hierarchy — with one important exception that the evidence is beginning to crystallise around elasticity, texture, and clarity specifically.

PDRN and Rejuran: The Healing Foundation Skin Booster

Rejuran, and the broader category of PDRN-based injectables, originated in South Korea’s wound-healing literature before migrating — rapidly and enthusiastically — into aesthetic practice. The active molecule, polydeoxyribonucleotide, is derived from salmon testicular DNA, a choice that sounds arresting at first but reflects sound biochemical reasoning: salmon PDRN has a high degree of structural compatibility with human DNA repair pathways.

The mechanism centres on adenosine A2A receptor activation, which drives an anti-inflammatory cascade and stimulates fibroblast proliferation. The clinical results in acne-scarred skin and photo-damaged skin are well-documented: improved texture, reduced redness, and a gradual thickening of the dermal layer. For patients in their late twenties and thirties dealing with the lingering aftermath of breakouts, PDRN treatments have become a genuine first-line recommendation.

Where PDRN treatments show their limits is in patients whose primary concern is loss of elasticity — the softening of facial contours, the crepe-like quality of perioral or periocular skin, the general deflation of a face that has lost its structural rebound. Here, the indirect collagen stimulation of PDRN, mediated through generalised healing rather than targeted fibroblast receptor engagement, is simply not the sharpest tool available.

Skinvive: Intelligent Hydration, A Skin Booster With Honest Limitations

Skinvive entered the US market in 2023 with FDA clearance and a focused indication: improving skin smoothness in the cheeks of adults. It is an HA-based product using Allergan’s VYCROSS technology — a cross-linking approach that produces a fluid, easily spreadable gel designed to disperse through the upper dermis and create a hydration depot rather than a volumising scaffold.

Its results are real and perceptible: patients consistently report softer, more luminous skin, with the kind of surface quality that photographers and make-up artists have historically referred to as “a good base.” The product’s approval data showed significant improvements in skin smoothness that persisted to six months in a majority of treated patients.

What Skinvive does not do — and has never claimed to do — is regenerate. The cross-linked HA attracts and retains water molecules in the dermis; it does not stimulate collagen synthesis, remodel the extracellular matrix, or alter the fibroblast’s production profile in any lasting way. When the product degrades, the benefits largely degrade with it. For patients whose primary goal is a reset of hydration and surface texture, that is an entirely appropriate trade-off. For those seeking structural improvement in skin elasticity, it addresses the symptom rather than the cause.

PDGF: The Case for Growth Factor-Led Regeneration Skin Booster

Platelet-Derived Growth Factor, specifically the PDGF-BB isoform, is a signalling protein with a well-established role in tissue repair. In the context of the skin, it binds to tyrosine kinase receptors on fibroblasts — the cells responsible for producing collagen, elastin, and hyaluronic acid — and initiates a downstream signalling cascade that directly upregulates synthesis of all three. This is not an indirect effect mediated through a generalised healing response; it is a targeted molecular conversation with the exact cells responsible for dermal architecture.

PDGF formulations for aesthetic use typically combine PDGF-BB with complementary growth factors, including Vascular Endothelial Growth Factor (VEGF) for improved microcirculation and Epidermal Growth Factor (EGF) for keratinocyte turnover. The effect of this combination is clinically distinct: patients treated with PDGF-based protocols report improvements in skin tone and clarity that go beyond what hydration alone can produce, alongside a firmness and resilience that reflects genuine structural change rather than surface softening.

The literature supporting PDGF’s superiority in elasticity outcomes is growing. Studies measuring dermal density by high-frequency ultrasound have shown statistically significant increases after PDGF treatment courses that are not replicated to the same degree by HA biorevitalisers. Collagen fibre organisation — the structural feature most strongly associated with elastic recoil — shows measurable improvement on dermoscopy and reflectance confocal microscopy in PDGF-treated skin. These are not cosmetic metrics; they are biological ones.

Clarity, too, is better addressed by PDGF through a mechanism that is worth understanding. The uneven, subtly dull quality of aged skin is partly a hydration issue — which HA can correct — but is also a consequence of disorganised keratinocyte turnover and compromised microvasculature. PDGF’s upregulation of VEGF activity improves dermal perfusion; its stimulation of EGF activity normalises the cell-cycling rate of the epidermis. The result is a skin surface that reflects light more uniformly and with greater luminosity, an effect that clinicians often describe as the skin looking “awake” rather than simply “hydrated.”

A New Standard for the Aging Skin Consultation

None of this is to suggest that a single product category answers all questions. A patient with active rosacea and post-inflammatory hyperpigmentation may derive more immediate benefit from PDRN’s anti-inflammatory action before any growth factor treatment is considered. A younger patient seeking pre-event skin optimisation — the kind of glow associated with a significant occasion — may find HA biorevitalisation a perfectly matched, lower-commitment option.

But for the patient who has begun to notice that their skin has lost its fundamental quality — the elasticity, the clarity, the texture of tissue that is regenerating healthily — the evidence increasingly points toward growth factor-led treatment as the category most likely to deliver outcomes that are structural rather than surface-level, cumulative rather than transient, and regenerative rather than merely cosmetic.

That distinction — regenerative versus cosmetic — is the defining question of modern aesthetic medicine. Skin boosters, at their best, answer it well. PDGF-based formulations, at this stage of the science, answer it most completely.